SGLT2 inhibitors are novel antihyperglycemic agents with the possibility to progress in glycemic management while posing an incredibly low risk of hypoglycemia, insulin independence, and cardioprotection. The gene discussed is SLC5A2; the disease is Hypoglycemia.